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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effectiveness of dietary modifications, specifically restriction of salt, alcohol and caffeine intake, in patients suffering
from Ménière’s disease or syndrome. We will also review other dietary modifications but we will limit analysis of these studies to a
narrative review.
B A C K G R O U N D
Description of the condition
Ménière’s disease or syndrome is a chronic inner ear disorder that
results in sporadic attacks of vertigo, sensorineural hearing loss,
aural fullness and tinnitus. The term ’Ménière’s disease’ refers to
an idiopathic disorder, but a clinically identical presentation can
occur secondary to other conditions, such as infections, genetic
disorders or trauma, and this is referred to as ’Ménière’s syndrome’.
In a large US study the prevalence of Ménière’s disease was esti-
mated at 200 per 100,000 people (Alexander 2010). It most com-
monly affects people between the ages of 40 and 60 years, with a
slight female preponderance (da Costa 2002). Acute attacks usu-
ally occur in clusters, with those affected often being symptom-free
for months in between. There is a higher frequency of attacks in
the initial period after presentation with an eventual reduction but
sustained deterioration in hearing (Moffat 1997). The number of
vertiginous episodes has been noted to cease eventually (Silverstein
1989).
At present no ’gold standard’ diagnostic test for Ménière’s disease
exists and the diagnosis is frequently based on the practitioner’s
assessment of the patient’s history and neurotologic evaluation.
The American Academy of Otolaryngology - Head and Neck
Surgery (AAO-HNS) has produced diagnostic guidelines (Alford
1972), which have since been revised twice (Ménière’s Guide 1995;
Pearson 1985). The guidelines state that a diagnosis can be made
if the following criteria are met:
• at least two spontaneous episodes of rotational vertigo
lasting at least 20 minutes;
• audiometric confirmation of a sensorineural hearing loss;
• tinnitus and/or a perception of aural fullness.
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When patients meet the AAO-HNS criteria and the symptoms are
attributed to a specific cause they are classified as having Ménière’s
syndrome.
Although the pathophysiology of Ménière’s disease is unknown,
there is thought to be an association with endolymphatic hydrops,
which is distortion of the membranous labyrinth due to the over
accumulation of endolymph (Hallpike 1938).
At present there is no definitive treatment for Ménière’s disease
and treatment options range from dietary modification through
medication to surgery. Two medications that have been used are
betahistine and diuretics. A Cochrane review, which was last up-
dated in 2010, concluded that there was no evidence of a benefit
from the use of betahistine in Ménière’s (James 2001). Another
Cochrane review looked at the use of diuretics and concluded that
there was insufficient evidence for or against the use of diuret-
ics in the treatment of Ménière’s disease or syndrome, due to the
fact that there were no studies that met the review inclusion crite-
ria (Burgess 2006). Other treatment modalities include intratym-
panic injections of gentamicin or dexamethasone. A Cochrane re-
view on the use of gentamicin found two studies that met the cri-
teria for inclusion and concluded that there was evidence for its
use in the treatment of Ménière’s disease or syndrome, although
it carries a risk of hearing loss (Pullens 2011). Surgical interven-
tion includes a vast number of procedures, which can be classified
as destructive and non-destructive. Destructive procedures aim to
control the individual’s vestibular symptoms by destroying their
vestibular function (e.g. labyrinthectomy or vestibular nerve sec-
tion). Non-destructive procedures are less invasive and aim to al-
ter the natural course of the disease (e.g. endolymphatic sac de-
compression or insertion of ventilation tubes (grommets)). A rel-
atively recent Cochrane review has looked at surgery for Ménière’s
disease but identified only two randomised controlled trials, both
of endolymphatic sac decompression, neither of which showed a
benefit of this surgical procedure (Pullens 2013).
Description of the intervention
It is suggested that high sodium levels may induce endolym-
phatic hydrops. The observation that water retention can exac-
erbate the symptoms of Ménière’s disease was first documented
in 1929 (Dederding 1929). Subsequent uncontrolled studies sug-
gested that the manipulation of salt intake influences the symp-
toms experienced by those suffering with Ménière’s (Furstenberg
1934; Furstenberg 1941). More recent studies of restricted salt
intake, usually together with other treatment modalities, such as
the use of diuretics, have also suggested better symptom control
in patients with Ménière’s disease (Klockhoff 1974; Santos 1993).
As such, dietary salt restriction is recommended by many clini-
cians. Excessive reduction in salt intake may, however, in extreme
and rare cases result in hyponatraemia, although this is more com-
monly due to specific diseases. Hyponatraemia is associated with
conditions ranging from mood disturbance to cerebral oedema
and possible death in extreme cases (Thompson 2010.)
Other dietary modifications include limiting the intake of alcohol
and caffeine (Luxford 2013). Both alcohol and caffeine can result
in vasoconstriction and a reduction in the blood supply to the
inner ear, which may make patients’ symptoms worse. Although
no recognised adverse effects of reducing alcohol consumption
in normal individuals have been documented, reduction in peo-
ple who have a dependency on alcohol can result in withdrawal
symptoms such as psychotic episodes and delirium tremens (Stern
2010). Caffeine is a commonly ingested substance found in liquid
form in beverages such as tea and coffee, and it is also found in
food such as chocolate. Caffeine is a recognised ergogenic aid even
at physiological levels and enhances concentration and alertness
whilst reducing fatigue. A reduction in the intake of caffeine may
lead to withdrawal effects in individuals who are accustomed to
its effects, which can result in symptoms ranging from mood dis-
turbance to headaches (Pesta 2013).
How the intervention might work
Disturbance of the volume and/or electrolyte composition of the
endolymph is considered to be the cause of the symptoms expe-
rienced by patients with Ménière’s disease. High dietary intake
of salt can affect the concentrations of electrolytes in the blood,
which in turn affects the composition of the endolymph. It has
been reported that high salt intake can contribute to attacks and
it therefore follows that dietary modification can be used to con-
trol both the volume and composition of the endolymph (Stahle
1984). Fluctuation in the composition and volume of the en-
dolymph is considered to contribute to the fluctuating nature of
the symptoms experienced by sufferers of Ménière’s.
Why it is important to do this review
Dietary modifications, including restriction of salt, caffeine and
alcohol intake, are widely recommended to those suffering with
Ménière’s. It is therefore important to conduct a systematic review
of randomised controlled trials of these dietary modifications in
patients suffering with Ménière’s disease.
O B J E C T I V E S
Todetermine the effectiveness of dietarymodifications, specifically
restriction of salt, alcohol and caffeine intake, in patients suffering
from Ménière’s disease or syndrome. We will also review other
dietary modifications but we will limit analysis of these studies to
a narrative review.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials. We will also
include cluster-randomised and cross-over trials.
Types of participants
Adult patients, aged 18 and over, with a diagnosis of Ménière’s
disease or syndrome.
We will classify studies according to the diagnostic criteria used
to diagnose Ménière’s disease or syndrome. We will grade those
using the AAO-HNS criteria, or equivalent, to define probable,
definite or certain Ménière’s as grade ’I’ studies and the remaining
studies as grade ’II’.
Settings will include both the community and hospital.
Types of interventions
The experimental intervention of interest is dietary modification,
specifically, salt, caffeine and alcohol restriction or substitution
(or both). The control intervention will be no modification of
these agents or the use of a placebo. We will also identify studies
where other dietarymodifications are investigated but wewill limit
analysis of these studies to a narrative review.
The main comparators will be placebo or no alteration in diet.
The main comparison pairs are:
• dietary restriction of salt versus no restriction or placebo;
• dietary restriction of caffeine versus no restriction or
placebo;
• dietary restriction of alcohol versus no restriction or placebo.
Other possible comparison pairs include:
• dietary restriction of salt versus dietary restriction of caffeine;
• dietary restriction of salt versus dietary restriction of alcohol;
• dietary restriction of alcohol versus dietary restriction of
caffeine;
• dietary restriction of salt + caffeine versus no restriction or
placebo;
• dietary restriction of salt + alcohol versus no restriction or
placebo;
• dietary restriction of alcohol + caffeine versus no restriction
or placebo.
We will exclude studies where dietary modification plus another
treatment modality (e.g. a pharmacological agent) is used due to
the potential for interactive effects. We will include studies where
multiple dietary restrictions are used in conjunction but we will
note this note in the analysis. We expect that there will be vari-
ability as to the level and duration of dietary modification, but we
will note this in the analysis.
Types of outcome measures
We will analyse the following outcomes in the review, but they
will not be used as a basis for including or excluding studies.
Primary outcomes
• Control of vertigo or decrease in vertigo attacks, as
suggested by the AAO-HNS* (Ménière’s Guide 1995), using the
results of the various questionnaire-based assessment tools
including the Vertigo Symptom Scale, the Vertigo Dizziness
Imbalance Questionnaire and the Dizziness Handicap Inventory
amongst others.
• Adverse effects, based on patient-reported symptoms as well
as the results of the specific questionnaires including the Vertigo
Symptom Scale, the Vertigo Dizziness Imbalance Questionnaire
and the Dizziness Handicap Inventory amongst others.
Secondary outcomes
• Hearing: progression of hearing loss, as measured by a pure-
tone audiogram.
• Severity of tinnitus, as measured by using patient-reported
questionnaire scores such as the Vertigo Dizziness Imbalance
Questionnaire.
• Perception of aural fullness, as measured by using patient-
reported questionnaire scores such as the Vertigo Dizziness
Imbalance Questionnaire.
• Functional impairment and disability, using the results of
the various questionnaires, particularly the Dizziness Handicap
Inventory.
• Overall changes in well-being and quality of life, as
reported in the Dizziness Handicap Inventory Questionnaire.
*The AAO-HNS Committee on Hearing and Equilibrium pro-
posed the “control of vertigo” as a main objective outcome mea-
sure when assessing therapy in Ménière’s disease. The number of
attacks six months prior to treatment are compared to the num-
ber in the period between 18 and 24 months following treatment.
The resulting number indicates the extent of “control of vertigo”.
The AAO-HNS further divides the control of vertigo into classes,
where Class A (CoV = 0) is complete control and class B (CoV
1 to 40) is substantial control. They recommend a period of at
least two years of follow-up in order to assess fully the effect of the
intervention. We will also consider studies with shorter periods of
follow-up for this review.
We also anticipate various questionnaire-based assessment tools
being used in the different studies, including the Vertigo Symp-
tom Scale (VSS), the Vertigo Dizziness Imbalance Questionnaire
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and the Dizziness Handicap Inventory amongst others. We will
include all forms of questionnaire that address the patient’s percep-
tion of their symptoms if used consistently. These questionnaires
will enable us to assess the impact on the patients’ quality of life,
functional impairment and disability.
The instruments to assess the outcomes of interest are therefore
pure-tone audiograms, which will address any change in hearing
loss or its progression (or both), and various questionnaires that
will address the remaining primary and secondary outcome mea-
sures.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct system-
atic searches for randomised controlled trials and controlled clin-
ical trials. There will be no language, publication year or publica-
tion status restrictions. We may contact original authors for clar-
ification and further data if trial reports are unclear and we will
arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• Cochrane Register of Studies ENT Trials Register (search to
date);
• Cochrane Central Register of Controlled Trials
(CENTRAL, current issue);
• PubMed (1946 to date);
• Ovid EMBASE (1974 to date);
• EBSCO CINAHL (1982 to date);
• Ovid AMED (1985 to date);
• Ovid CAB abstracts (1910 to date);
• LILACS (search to date);
• KoreaMed (search to date);
• IndMed (search to date);
• PakMediNet (search to date);
• Web of Knowledge, Web of Science (1945 to date);
• CNKI (searched via Google Scholar to date);
• ClinicalTrials.gov (www.clinicaltrials.gov) (search via the
Cochrane Register of Studies to date);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (search to date);
• ISRCTN (www.isrctn.com) (search to date);
• Google Scholar (search to date);
• Google (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these will be combined with subject strategy adaptations of
the highly sensitive search strategy designed by Cochrane for iden-
tifying randomised controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Information Specialist will search PubMed, TRIPdatabase, The
Cochrane Library and Google to retrieve existing systematic re-
views relevant to this systematic review, so that we can scan their
reference lists for additional trials. We will search for conference
abstracts using the Cochrane ENT Trials Register and EMBASE.
Data collection and analysis
Selection of studies
Two authors (KH and LM) will independently scan the initial
search results to identify trials that appear to meet the inclusion
criteria. Theywill use abstract review to eliminate any trials that are
clearly ineligible. If either author identifies the paper as potentially
suitable, we will review the full text of the article. We will resolve
disagreements by discussion or, failing that, with the input of the
third author (AS).
Data extraction and management
Twoauthors (KHandLM)will extract data independently.Wewill
use standardised data extraction forms. There will be no blinding
of journal, author names or affiliations.
For each study, we will extract the following information:
• study design;
• duration of study;
• randomisation;
• allocation concealment;
• number of participants;
• setting of study;
• diagnostic criteria;
• exclusion criteria;
• age and sex distribution of participants;
• country of recruitment;
• co-morbidity;
• date of study;
• number of intervention groups;
• type of dietary modification;
• outcomes measured and definition of outcomes;
• missing data and final sample size.
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Assessment of risk of bias in included studies
KH and LM will undertake assessment of the risk of bias of the
included trials independently, with the following taken into con-
sideration, as guided by theCochrane Handbook for Systematic Re-




• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.3 (
RevMan 2014), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
adequacy of each entry: ’low’, ’high’ or ’unclear’ risk of bias.
Wewill also judge two extra domains: the certainty of the diagnosis
of Ménière’s (see also Types of participants) and the quality of
outcome assessment (see Types of outcome measures). However,
we will report and address these domains in the ’Characteristics of
included studies’ table rather than consider them as a risk of bias
domain.
Measures of treatment effect
We will use appropriate statistical tests based on the data. For
dichotomous data we will calculate an odds ratio (OR), risk ratio
(RR) and risk difference (RD, also called absolute risk reduction),
as well as the number of participants needed to treat to avoid a
case of the disease (number needed to treat to benefit - NNTB)
from the pooled results, based on the median risk in the control
groups.
For the intervention effect measures of continuous data we plan to
calculate the difference in means (mean difference, MD) between
the groups, provided that different studies are using the same scale
of measurement. We plan to calculate the standardised mean dif-
ference (SMD) if different scales are used.
For ordinal data we will check to see whether the scale used has
been validated. Depending on the number points in these scales
(and how the data were reported), we will either dichotomise these
or analyse them as continuous outcomes.
Unit of analysis issues
Cluster-randomised trials
Cluster-randomised trials allocate groups instead of individuals.
The participants in each group may be related in some way, there-
fore this needs to be taken into account in the analysis otherwise
there is a unit of analysis error, which would produce an artificially
smaller P value and a risk of false positive results. For this purpose
we will use a special statistical method, as detailed in chapter 16.3
of the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), with the appropriate statistical advice.
Cross-over trials
Cross-over trials may have a carry-over effect. For this reason we
will use data from cross-over trials only if data from before the
cross-over can be obtained.
Multi-arm studies
If we find studies with more two groups (e.g. two or more active
treatments being tested against placebo), we will establish which
of the comparisons are relevant to the systematic review and rele-
vant to each of the meta-analyses that we may implement. If the
study design uses independent groups, we will treat the study as
independent comparisons. However, if we encounter participants
that have been included in several groups, there is a risk of unit of
analysis error andwewill ensure that participants are only included
once per meta-analysis as per chapter 16.5 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011).
Repeated observations on participants
In longer studies, results may be recorded at more than one time
interval. In order to avoid unit of analysis error when combining
these results in a single meta-analysis (and therefore counting the
same participants in more than one comparison), we will aim
to retrieve individual patient data and perform a time-to-event
analysis using the whole follow-up for each participant.
We will also aim to establish short-term (three months), medium-
term (12 months) and long-term (over 24 months) effects.
Dealing with missing data
When the required data are not available in published accounts,
we will contact the principal investigator to request the data. If no
useful response is obtained, we will treat missing data differently if
they are judged to be ’missing at random’, in which case the effect
may not be important, or ’not missing at random’, where missing
data may affect the overall result. In the first case, the data can be
ignored. If large numbers of drop-outs are found, we will conduct
sensitivity analysis with different assumptions.
We will be alert to potential mislabelling or non-identification of
standard errors and standard deviations. Unless missing standard
deviations can be derived from confidence intervals we will not
assume values for analysis purposes.
Assessment of heterogeneity
We will assess studies for clinical, statistical and methodological
heterogeneity. If sufficient non-heterogeneous studies are found,
wewill subject the data to ameta-analysis with a fixed-effectmodel
5Restriction of salt intake and other dietary modifications for the treatment of Ménière’s disease or syndrome (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
where applicable. If there is statistical heterogeneity, we will use
random-effects modelling. If the level of heterogeneity and the
appropriate model that should be used is unclear, we will take
statistical advice.
Assessment of reporting biases
If an individual meta-analysis contains at least 10 studies, we will
assess publication bias using funnel plots and Egger’s test.
Data synthesis
Analysis will be on an intention-to-treat basis. If the data are com-
patible we will combine data to give summary measures of effect.
If data are missing we will use available case analysis - using all
data (as reported) for all randomised patients available at the end
of the trial/time point of interest, regardless of actual treatment
received.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available, we will undertake subgroup analysis
based on:
• meeting/not meeting the AAO-HNS criteria;
• the treatment protocol (i.e. the nature of salt, caffeine or
alcohol restriction and the duration of dietary modification).
Sensitivity analysis
We will conduct a sensitivity analysis by comparing the effect of
the inclusion and exclusion of studies with different risk of bias. If
we deem studies to have a high risk of bias, we will exclude them
from the analysis.
GRADE and ’Summary of findings’ table
We will use the GRADE approach to rate the overall quality of
evidence. The quality of evidence reflects the extent to which we
are confident that an estimate of effect is correct and we will apply
this in the interpretation of results. There are four possible ratings:
high, moderate, low and very low. A rating of high quality of
evidence implies that we are confident in our estimate of effect
and that further research is very unlikely to change our confidence
in the estimate of effect. A rating of very low quality implies that
any estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We will include a ’Summary of findings’ table, constructed ac-
cording to the recommendations described in Chapter 10 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011).Wewill include the following comparisons and
outcomes in our ’Summary of findings’ table(s):
• proportion of patients with control of vertigo or decrease in
vertigo attacks (as suggested by the AAO-HNS);
• proportion of patients with adverse effects;
• proportion of patients with loss or gain of hearing/
reduction in progression of hearing loss;
• proportion of patients with a reduction in the severity of
tinnitus;
• proportion of patients with a reduction in the perception of
aural fullness;
• functional impairment and disability;
• overall changes in well-being and quality of life.
A C K N OW L E D G E M E N T S
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure, Cochrane Programme
Grant or Cochrane Incentive funding to Cochrane ENT. The
views and opinions expressed therein are those of the authors and
do not necessarily reflect those of the Systematic Reviews Pro-
gramme, NIHR, NHS or the Department of Health.
6Restriction of salt intake and other dietary modifications for the treatment of Ménière’s disease or syndrome (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Alexander 2010
Alexander TH, Harris JP. Current epidemiology of Meniere’s
syndrome. Otolaryngologic Clinics of North America 2010;
43(5):965–70.
Alford 1972
Alford BR. Disease: criteria for diagnosis and evaluation
of therapy for reporting. Report of subcommittee on
equilibrium and its measurement. Transactions of the
American Academy of Ophthalmology and Otolaryngology
1972;76:1462–4.
Burgess 2006
Burgess A, Kundu S. Diuretics for Ménière’s disease or
syndrome. Cochrane Database of Systematic Reviews 2006,
Issue 3. [DOI: 10.1002/14651858.CD003599.pub2]
da Costa 2002
da Costa SS, de Sousa LC, Piza MR. Meniere’s disease:
overview, epidemiology and natural history. Otolaryngologic
Clinics of North America 2002;35(3):455–95.
Dederding 1929
Dederding D. Clinical and experimental examination in
patients suffering from morbus Meniere including study
of problems of bone conduction. Acta Oto-Laryngologica
1929;10:1–156.
Furstenberg 1934
Furstenberg AC, Lashmet FH, Lathrop F. Meniere’s
symptom complex: medical treatment. Annals of Otology,
Rhinology and Laryngology 1934;43:1035–47.
Furstenberg 1941
Furstenberg AC, Richardson G, Lathrop FD. Meniere’s
disease: addenda to medical therapy. Archives of
Otolaryngology 1941;34:1038–92.
Hallpike 1938
Hallpike C, Cairns H. Observations on the pathology of
Menière’s syndrome. Journal of Laryngology and Otology
1938;53:625–55.
Handbook 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
James 2001
James AL, Burton ML. Betahistine for Meniere’s disease or
syndrome. Cochrane Database of Systematic Reviews 2001,
Issue 1. [DOI: 10.1002/14651858.CD001873]
Klockhoff 1974
Klockhoff I, Lindbloom U, Stahle J. Diuretic treatment of
Meniere’s disease: long-term results with chlorothiazide.
Archives of Otolaryngology 1974;100:262–5.
Luxford 2013
Luxford E, Berliner KI, Lee J, Luxford WM. Dietary
modification as adjunct treatment in Ménière’s disease:
patient willingness and ability to comply. Otology &
Neurotology 2013;34(8):1438–43.
Moffat 1997
Moffat DA, Ballagh RH. Menière’s disease. In: Kerr AG,
Booth JB editor(s). Scott-Brown’s Otolaryngology. 3rd
Edition. Vol. 3, Oxford: Butterworth-Heinemann, 1997:
1–50.
Ménière’s Guide 1995
No authors listed. Committee on Hearing and Equilibrium.
Guidelines for the diagnosis and evaluation of therapy in
Menière’s disease. Otolaryngology - Head and Neck Surgery
1995;113:181–5.
Pearson 1985
Pearson BW, Brackmann DE. Committee on hearing and
equilibrium guidelines for reporting treatment results in
Menière’s disease. Otolaryngology - Head and Neck Surgery
1985;93:578–81.
Pesta 2013
Pesta DH, Angadi SS, Burtscher M, Roberts CK. The effects
of caffeine, nicotine, ethanol, and tetrahydrocannabinol on
exercise performance. Nutrition and Metabolism 2013;10
(1):71.
Pullens 2011
Pullens B, van Benthem PP. Intratympanic gentamicin
for Ménière’s disease or syndrome. Cochrane Database
of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/
14651858.CD008234.pub2]
Pullens 2013
Pullens B, Verschuur HP, van Benthem PP. Surgery for
Ménière’s disease. Cochrane Database of Systematic Reviews
2013, Issue 2. [DOI: 10.1002/14651858.CD005395.pub3]
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Santos 1993
Santos PM, Hall RA, Snyder JM, Hughes LF, Dobie RA.
Diuretic and diet effect on Menière’s disease evaluated
by the 1985 Committee on Hearing and Equilibrium
guidelines. Otolaryngology - Head and Neck Surgery 1993;
109(4):680–9.
Silverstein 1989
Silverstein H, Smouha E, Jones R. Natural history versus
surgery for Menière’s disease. Otolaryngology - Head and
Neck Surgery 1989;100:6–16.
Stahle 1984
Stahle J. Medical treatment of fluctuant hearing loss in
Meniere’s disease. American Journal of Otology 1984;5(6):
529–33.
Stern 2010
Stern TA, Gross AF, Stern TW, Nejad SH, Maldonado
JR. Current approaches to the recognition and treatment
7Restriction of salt intake and other dietary modifications for the treatment of Ménière’s disease or syndrome (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of alcohol withdrawal and delirium tremens: “old wine in
new bottles” or “new wine in old bottles”. Primary Care
Companion to The Journal of Clinical Psychiatry 2010;12(3):
PCC.10r00991.
Thompson 2010
Thompson CJ. Hyponatraemia: new associations and new
treatments. European Journal of Endocrinology 2010;162:
S1–S3.
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Endolymphatic Hydrops] explode all trees
#2 meniere*
#3 (endolymphatic or cochlea*) and hydrops
#4 (aural or labyrinth*) and (hydrops or syndrome or vertigo)
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Diet, Sodium-Restricted] explode all trees
#7 MeSH descriptor: [Food Habits] explode all trees
#8 MeSH descriptor: [Diet Therapy] this term only
#9 MeSH descriptor: [Sodium, Dietary] explode all trees
#10 MeSH descriptor: [Caffeine] explode all trees
#11 MeSH descriptor: [Drinking Behavior] explode all trees
#12 salt* or sodium*
#13 Caffein* or decaffein* or “de caffein*” or de-caffein* or coffee or tea or alcohol*
#14 (diet* or food) and (restrict* or modif* or habit* or free*)
#15 nutrition*
#16 Any MeSH descriptor with qualifier(s): [Diet therapy - DH]
#17 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #5 and #17
#19 MeSH descriptor: [Endolymphatic Hydrops] explode all trees and with qualifier(s): [Diet therapy - DH]
#20 #18 or #19
C O N T R I B U T I O N S O F A U T H O R S
KH will obtain studies. KH and LM will select studies, extract data and assess risk of bias. KH will enter data into RevMan, and carry
out and interpret the analysis. AS will provide advice as needed throughout. KH, LM and AS will draft the final review. KH will have
responsibility for updating and maintaining the review.
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